Frank P. Zemlan
Directeur Général chez Phase 2 Discovery, Inc.
Profil
Frank P.
Zemlan is Chief Executive Officer of Phase 2 Discovery, Inc. He has over 20 years of experience in clinical research at Merck & Co., Inc., Aventis, Inc., and GlaxoSmithKline Plc.
Dr. Zemlan holds a PhD.
Postes actifs de Frank P. Zemlan
| Sociétés | Poste | Début |
|---|---|---|
Phase 2 Discovery, Inc.
 Phase 2 Discovery, Inc. Pharmaceuticals: MajorHealth Technology Phase 2 Discovery, Inc. (P2D) develops central nervous system drugs. The company provides discovery research & development services for pharmaceutical and biotechnology companies. It also develops drugs for treating psychiatric and neurologic disorders. Its products include PD6735, the treatment of primary insomnia and additional indications, N-Substituted Analogs of Benztropine for the treatment of attention deficit hyperactivity disorder & Thiothalidomides and Hydroxythalidomides for the treatment of ALS and MS. Phase 2 Discovery was founded in 1998 and is headquartered in Cincinnati, OH. | Directeur Général | - |
Anciens postes connus de Frank P. Zemlan
| Sociétés | Poste | Fin |
|---|---|---|
| Aventis, Inc. | Corporate Officer/Principal | - |
| GSK PLC | Corporate Officer/Principal | - |
| MERCK & CO., INC. | Corporate Officer/Principal | - |
Formation de Frank P. Zemlan
| Villanova University | Graduate Degree |
| University of Pennsylvania | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| MERCK & CO., INC. | Health Technology |
| GSK PLC | Health Technology |
| Entreprise privées | 2 |
|---|---|
Phase 2 Discovery, Inc.
Phase 2 Discovery, Inc. Pharmaceuticals: MajorHealth Technology Phase 2 Discovery, Inc. (P2D) develops central nervous system drugs. The company provides discovery research & development services for pharmaceutical and biotechnology companies. It also develops drugs for treating psychiatric and neurologic disorders. Its products include PD6735, the treatment of primary insomnia and additional indications, N-Substituted Analogs of Benztropine for the treatment of attention deficit hyperactivity disorder & Thiothalidomides and Hydroxythalidomides for the treatment of ALS and MS. Phase 2 Discovery was founded in 1998 and is headquartered in Cincinnati, OH. | Health Technology |
| Aventis, Inc. |
